The industry group FarmaBrasil, representing twelve leading pharmaceutical companies in Brazil, has voiced strong opposition to a legislative proposal intended to extend the patent duration for certain medications, notably Ozempic, which has its patent set to expire in March. These companies are eager to produce generic versions of the drug once the patent expires, allowing for more affordable alternatives. FarmaBrasil argues that this proposed law, referred to as PL do Ozempic, creates legal uncertainties and could have immediate negative effects on drug prices and public access to medications.

The current proposal, known as PL 5810/2025, seeks to extend patent protections under the condition of alleged administrative delays in the evaluation by the National Institute of Industrial Property (INPI). Critics, including the Vice President of Brazil, Geraldo Alckmin, have expressed concern that prolonging the exclusivity period for drugs nearing patent expiration undermines competition and restricts the availability of much-needed lower-priced medicines.

Although the proposal has yet to be approved by the relevant commissions, it has stirred significant debate surrounding healthcare financing in Brazil. The apprehensions raised by FarmaBrasil highlight the tension between innovative pharmaceutical developments and the urgent need for affordable healthcare solutions, particularly as public health expenditures are already under strain. The outcomes of this legislative process could have lasting implications for patients and the healthcare system in Brazil.